Jazz Pharmaceuticals Files 8-K Report

Ticker: JAZZ · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1232524

Jazz Pharmaceuticals PLC 8-K Filing Summary
FieldDetail
CompanyJazz Pharmaceuticals PLC (JAZZ)
Form Type8-K
Filed DateNov 21, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

Related Tickers: JAZZ

TL;DR

Jazz Pharma filed a routine 8-K, mostly financial exhibits. Nothing major to see here.

AI Summary

On November 20, 2024, Jazz Pharmaceuticals plc filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosure rather than a major event. No specific financial figures or new business developments were detailed in the provided excerpt.

Why It Matters

This filing serves as a public record of Jazz Pharmaceuticals' disclosures to the SEC, providing transparency for investors and stakeholders regarding company events and financial information.

Risk Assessment

Risk Level: low — The filing appears to be a standard disclosure of financial statements and exhibits, not indicating any immediate or significant risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The provided excerpt states that the filing includes 'Financial Statements and Exhibits' but does not list the specific documents included.

What is the exact date of the earliest event reported in this 8-K?

The earliest event reported is dated November 20, 2024.

Where are Jazz Pharmaceuticals plc's principal executive offices located?

The principal executive offices are located at Fifth Floor, Waterloo Exchange, Waterloo Road, Dublin 4, Ireland.

What is the IRS Employer Identification Number for Jazz Pharmaceuticals plc?

The IRS Employer Identification Number is 98-1032470.

Under which section of the Securities Exchange Act of 1934 is this report filed?

This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Filing Stats: 495 words · 2 min read · ~2 pages · Grade level 12.1 · Accepted 2024-11-21 06:06:02

Key Financial Figures

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated November 20, 2024. 104 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY By: /s/Neena Patil Name: Neena Patil Title: Executive Vice President and Chief Legal Officer Date: November 21, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing